Our Mission
A Targeted, Inhaled Approach to Severe Asthma
Despite optimized care, breakthrough exacerbations drive morbidity, mortality, and healthcare utilization. Current biologics target primarily the Th2 pathway, leaving many patients without adequate relief.
Parteo Therapeutics is developing an inhaled small molecule that targets mast cells, the upstream driver of asthma exacerbations, directly in the lung. By focalizing therapy where it matters most, we aim to deliver superior efficacy with an improved safety profile.
